Huino's AI CDSS 'Vital Picasso' Receives Medical Device Manufacturing Certification from Ministry of Food and Drug Safety
Huino's artificial intelligence (AI)-based Clinical Decision Support System (CDSS), ‘Vital Picasso’, has received medical device manufacturing certification from the Ministry of Food and Drug Safety.
According to Huino on July 3, Vital Picasso is a software (S/W) used to predict the risk of cardiac arrest in adult patients aged 19 and over who are admitted to general wards. It analyzes collected vital sign data using an AI algorithm and provides a risk prediction score for cardiac arrest within 24 hours.
Huino plans to expedite the clinical introduction of Vital Picasso based on this manufacturing certification from the Ministry of Food and Drug Safety and its status as an innovative medical device. In particular, it aims to strengthen its hospital-centered digital healthcare portfolio by linking with existing commercialized products such as the long-term electrocardiogram analysis solution ‘MemoCare’ and the real-time in-hospital patient monitoring solution ‘MemoQ’.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Youngjun Gil, CEO of Huino, stated, “With MemoCare and MemoQ already commercialized in the fields of long-term electrocardiogram analysis and real-time in-hospital patient monitoring, respectively, Vital Picasso has now also secured a foundation for commercialization through this manufacturing certification. Based on this, we will further strengthen our position as a comprehensive digital healthcare platform encompassing diagnostic support, real-time monitoring, and clinical prediction.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.